

GENDER DIFFERENCE IN SEIZURE SENSITIVITY: ROLE OF STEROIDS AND NEUROACTIVE STEROIDS

Stefano Loizzo (a), Gabriele Campana (b), Anna Capasso (c), Loredana Costa (a), Andrea Fortuna (a), Flavia Franconi (d), Gabriella Galletta (a), Irene Guarino (a), Paolo Renzi (e), Santi Spampinato (b), Stefano Vella (a), Alberto Loizzo (a)

(a) *Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy*

(b) *Department of Pharmacology, University of Bologna, Italy*

(c) *Department of Pharmacological Sciences, University of Salerno, Italy*

(d) *Department of Pharmacology, University of Sassari, Italy*

(e) *Department of Psychology, Sapienza University of Roma Italy*

Background

To be men or women is one of the most important determinants of human health, and sex-related vulnerability in brain and body development are described in humans for many conditions, including cerebral excitability, metabolic and immune diseases, etc. Experimental studies in male rodents suggest that stressful events during lactation could have a role in determining metabolic-neurophysiological features of the adult life (programming), but sex-dependent dimorphic studies on programming modulation following neonatal stressful procedures and drug treatment are scanty.

Procedures

In male mice, daily neonatal handling, i.e., psychological distress (10 min of maternal separation) associated to a mild painful stimulus (sham injection) for the whole lactation period, produces long term overweight associated with variations in lipid and glucose homeostasis, immunological upset, break-down of some hypothalamus-pituitary-adrenal (HPA) feed-back mechanisms. Upset of hormones levels appear of particular importance for the triggering of said metabolic conditions. In this paper we investigate: i) whether these alterations are accompanied by brain metabolic and functional alterations; ii) whether alterations can be modulated through repeated treatment with a drug (naloxone) antagonist to the endogenous μ - and δ -opioid system, and with a drug (antisense oligonucleotide inhibitor of proopiomelanocortin- AS); iii) whether these effects are sex-related; and iv) whether these effects can be reproduced in outbred (CD1) as well as in inbred (DBA/2 and C57Bl/6) mice.

Results

– *Body metabolic pattern*

Body metabolic features in handled male mice are consistently different from control animals, and similar to a type-2 diabetes mellitus pattern (body weight at 90 days of age +7.5%; basal fasting glycaemia +42%; plasma insulin + 125%; corticosterone +110%; ACTH +169%, epididymal fat pads weight – an abdomen obesity sign – +74%).

Conversely, adult female mice do not show consistent hormonal, behavioural and metabolic alterations following neonatal handling.

- *Cerebral excitability*

Following neonatal handling, male DBA/2 showed consistently less epileptiform pattern *versus* controls (polyspike-and-waves complexes *per* recording hour, mean 8.5 ± 3.1 *versus* 27.6 ± 6.5 , $p < 0.05$; $n=6$), whereas handled female mice show EEG epileptiform pattern not significantly different from controls.

- *Brain neurophysiology & metabolic pattern*

N1, N2 and N3 peaks of flash-evoked response (VEPs) showed a faster reactivity in manipulated male mice *versus* controls (-9.3%); this corresponded to a different NAD(P)H fluorescence imaging of *ex vivo* isolated brain visual cortex, i.e., $+32.3\%$ more elevated deflection of the second part of the curve $\Delta F/F$ (re-charge). Different VEPs effects (to be studied) were found in male and female mice of different strains.

- *Drug effects*

Some parameters, such as body weight, epididymal fat pad (not fasting glycaemia, nor insulinemia), NAD(P)H fluorescence imaging and VEPs were normalized in formerly manipulated and naloxone-treated adult mice, whereas all parameters were drawn to control values in formerly manipulated and AS-treated adult mice.

Conclusions

These results indicate that the onset of sex differences may be very precocious, and that sex is an independent variable for the developmental programming in the brain-body relationship, presumably through the sex-dependent modulation of hypothalamus-pituitary-adrenal feedback mechanisms (bound also to cerebral excitability) following neonatal stressful procedures.

Publications of the project

- Capasso A, Loizzo A. Functional interference of dexamethasone on some morphine effects: hypothesis for the steroid-opioid interaction. *Recent Patents CNS Drug Discov* 2008;3(2):138-50.
- Franconi F, Diana G, Fortuna A, Galiotta G, Trombetta G, Valentini G, Seghieri G, Loizzo A. Taurine administration during lactation modifies hippocampal CA1 neurotransmission and behavioural programming in adult male mice. *Brain Res Bull* 2004;63(6):491-7.
- Franconi F, Loizzo A, Ghirlanda G, Seghieri G. Taurine supplementation and diabetes mellitus. *Curr Opin Clin Nutr Metab Care* 2006;9(1):32-6.
- Galiotta G, Giuliani G, Loizzo A, Amat AG, Fumagalli E, De Feo V, Quaranta E, Paladino L, Capasso A. Neurophysiological studies of *Heteropteris glabra* Hok. & Arn. (*Malpighiaceae*) in DBA/2J mice. *J Ethnopharmacol* 2005;97(3):415-9. *Erratum in: J Ethnopharmacol* 2005;99(3):411.
- Galiotta G, Loizzo A, Loizzo S, Trombetta G, Spampinato S, Campana G, Capasso A, Palermo M, Guarino I, Franconi F. Administration of antisense oligonucleotide against pro-opiomelanocortin prevents enduring hormonal alterations induced by neonatal handling in male mice. *Eur J Pharmacol* 2006;550(1-3):180-5.
- Guarino I, Loizzo S, Lopez L, Fadda A, Loizzo A. A chronic implant to record electroretinogram, visual evoked potentials and oscillatory potentials in awake, freely moving rats for pharmacological studies. *Neural Plast* 2004;11(3-4):241-50.

- Loizzo A, Carta S, Bennardini F, Coinu R, Loizzo S, Guarino I, Seghieri G, Ghirlanda G, Franconi F. Neonatal taurine administration modifies metabolic programming in male mice. *Early Hum Dev* 2007;83(10):693-6.
- Loizzo A, Loizzo S, Galiotta G, Caiola S, Spampinato S, Campana G, Seghieri G, Ghirlanda G, Franconi F. Overweight and metabolic and hormonal parameter disruption are induced in adult male mice by manipulations during lactation period. *Pediatr Res* 2006;59(1):111-5.
- Loizzo S, Costa L, Guarino I, Capasso A, Fortuna A, Loizzo A. A neurophysiological approach to gender studies: Flash-visual evoked responses in male and female mice in two inbred strains. Manuscript in preparation.
- Loizzo S, Fortuna A, Pieri M, Zona C, Ferri A, Carri MT, Vella S. Dynamic NAD(P)H post synaptic autofluorescence signals for the assessment of mitochondrial function in neurodegenerative diseases: monitoring the primary motor cortex of G93A mice, an amyotrophic lateral sclerosis model. Manuscript in preparation.
- Loizzo S, Guarino I, Fortuna A, Loizzo A. Fluorescence monitoring of mitochondrial components of oxidative phosphorylation of post-synaptic activation in neocortical slices in the mouse. *Pharmacologyonline* 2007;1:8-13.
- Loizzo S, Vella S, Fortuna A, Galiotta G, Guarino I, Costa L, Capasso A, Renzi P, Spampinato S, Campana G, Loizzo A. Brain and body metabolic and functional derangement in non-genetic type-2 diabetes model in male mice. Manuscript in preparation.
- Loizzo S, Vella S, Loizzo A, Galiotta G, Fortuna A, Frajese GV, Agrapart V, Ramirez Morales R, Capasso A, Guarino I, Carta S, Carru C, Zinellu A, Ghirlanda G, Seghieri G, Spampinato S, Campana G, Franconi F. Sexual Dimorphic Evolution of Epigenetic Programming in Non-Genetic Non-Alimentary Overweight Model in Mice. Manuscript in preparation.
- Seghieri G, Tesi F, Bianchi L, Loizzo A, Saccomanni G, Ghirlanda G, Anichini R, Franconi F. Taurine in women with a history of gestational diabetes. *Diabetes Res Clin Pract* 2007;76(2):187-92.

Patents

- Franconi F, Fortuna A, Campana G, Campanella C, Capasso A, Del Basso Orsini P, Fabi F, Galiotta G, Guarino I, Loizzo A, Loizzo A, Loizzo S, Renzi P, Spampinato SM, Trombetta G, inventors; Antisense oligonucleotides versus pituitary pro-opiomelanocortin, and their therapeutic application for the prevention and treatment of post-traumatic stress disorder (PTSD). Patent application n. RM2007A000005. 05 Gen 2007.